| Identification | Back Directory | [Name]
Benzoic acid, 4-[2-[(Z)-(4,5-dihydro-6-methyl-3,4-dioxofuro[3,4-c]pyridin-1(3H)-ylidene)methyl]-5-(hydroxymethyl)-1H-pyrrol-1-yl]-, ethyl ester | [CAS]
2411744-76-6 | [Synonyms]
α-Glucosidase-IN-11
Benzoic acid, 4-[2-[(Z)-(4,5-dihydro-6-methyl-3,4-dioxofuro[3,4-c]pyridin-1(3H)-ylidene)methyl]-5-(hydroxymethyl)-1H-pyrrol-1-yl]-, ethyl ester | [Molecular Formula]
C23H20N2O6 | [MOL File]
2411744-76-6.mol | [Molecular Weight]
420.41 |
| Hazard Information | Back Directory | [Uses]
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC50 value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels[1]. | [in vivo]
α-Glucosidase-IN-11 (compound 3k) (gastric gavage, 60 mg/kg, everyday, 4 weeks) can improve blood glucose levels during fasting[1].
| Animal Model: | Male Sprague Dawley rats (250e320g)[1] | | Dosage: | 60 mg/kg | | Administration: | Gastric gavage; everyday; 4 weeks | | Result: | Caused a significant drop in fasting blood glucose during the first and second weeks but did not cause a decrease in non-fasting blood glucose for up to four weeks. |
| [References]
[1] Tania Luthra, et al. Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes. Eur J Med Chem. 2020 Feb 15;188:112034. DOI:10.1016/j.ejmech.2020.112034 |
|
|